Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
goserelin acetate
|
| gptkbp:approvedBy |
1990s
|
| gptkbp:ATCCode |
gptkb:L02AE03
|
| gptkbp:brand |
gptkb:goserelin
|
| gptkbp:contraindication |
pregnancy
hypersensitivity to goserelin |
| gptkbp:countryOfOperation |
gptkb:United_Kingdom
gptkb:United_States |
| gptkbp:drugClass |
hormone therapy
|
| gptkbp:duration |
12 weeks
|
| gptkbp:form |
implant
10.8 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Zoladex LA
|
| gptkbp:indication |
gptkb:cancer
prostate cancer assisted reproduction endometriosis uterine fibroids |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:mechanismOfAction |
GnRH agonist
|
| gptkbp:pregnancyCategory |
X
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
decreased libido
mood changes sweating hot flashes bone density loss |
| gptkbp:storage |
below 25°C
|
| gptkbp:bfsParent |
gptkb:Zoladex
|
| gptkbp:bfsLayer |
7
|